Upfront Briefing
Blackstone handed Apogee up to $1.3B and didn't ask for a single share in return — non-dilutive is the new flex. Sanofi's venglustat grabbed US priority review in type 3 Gaucher, and GSK finally showed its homework on bepirovirsen in hepatitis B (spoiler: an actual functional cure). Net-net: late-stage money is cheap if your data's good, the FDA clocks are speeding up, and timelines are still the only thing that move models.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,520.4 |
0.0% |
9.7% |
| Nasdaq 100 |
29,973.6 |
(0.1%) |
18.9% |
| Russell 2000 |
2,919.9 |
0.0% |
16.4% |
| Healthcare (XLV) |
148.8 |
0.2% |
(4.3%) |
| Biotech (XBI) |
134.4 |
0.8% |
10.6% |
| Nasdaq Biotech (NBI) |
5,931.3 |
0.3% |
3.9% |
| Clinical Trials (BBC) |
43.6 |
0.4% |
15.8% |
|
- Records on autopilot — just don't look under the hood: the Dow tagged a fresh high (+0.4%) mostly because crude took a ~5.5% dive on Strait of Hormuz headlines, the S&P (+0.02%) limped to its own record, and the Nasdaq got mugged by a chip pullback as Micron gave back part of its moonshot.
- Biotech didn't wait for the macro — XBI (+0.8%) was the green standout, riding its own catalyst tape: Apogee's $1.3B Blackstone bag, GSK/Ionis' hep B cure data, and Sanofi's GD3 priority review.
- Market data: U.S. cash close Wednesday, 27 May 2026.
The Big 3
|
1
|
Blackstone backs Apogee AD therapy ahead of Phase 3
|
- Apogee dropped fresh Apex Part B Phase 2 data for zumilokibart (anti-IL-13 mAb) — 65.9% of mid-dose patients hit EASI-75 at 16 weeks — and walked away with up to $1.3B from Blackstone to bankroll Phase 3 and launch. Shares popped ~16%. Not a bad Wednesday.
- Why it matters: The capital is non-dilutive — up to $800M synthetic royalty plus up to $500M senior debt, staged ($100M at signing, $100M at Phase 3 enrolment, $200M on positive data), with low-to-mid single-digit royalties over 15 years that lapse above $8B in sales. It funds three Phase 3 trials (2H26 start) without tapping equity and sets up zumilokibart's less-frequent dosing against Dupixent and Ebglyss in a multibillion-dollar AD market.
- Source: BioCentury More: Fierce
|
|
2
|
Sanofi’s venglustat gets US priority review in Gaucher 3
|
- Sanofi’s venglustat was accepted for priority review in the US to treat type 3 Gaucher disease. The designation shortens the regulatory path for the rare-disease asset.
- Why it matters: Priority review sets a 25 November 2026 PDUFA date for venglustat, an oral, brain-penetrant glucosylceramide synthase inhibitor. Backed by Phase 3 LEAP2MONO (oral venglustat vs IV enzyme replacement), it could become the first US therapy for the neurological manifestations of GD3 — a defined rare-disease catalyst and an extension of Sanofi's lysosomal-storage franchise.
-
Source:
PR
-
More:
PR
|
| 3 | GSK details positive Phase 3 HBV data for Ionis-licensed drug |
- GSK and partner Ionis reported detailed pivotal data for bepirovirsen, a finite six-month antisense (ASO) therapy for chronic hepatitis B — published in NEJM and presented at EASL. Pooled B-Well 1/2 showed a 19% functional cure rate (233/1,220) vs 0% on standard of care (p<0.001), rising to 26% in patients with lower viral load.
- Why it matters: Functional cure is the prize in CHB, where current nucleos(t)ide analogues deliver ~1% annual cure and lifelong therapy. A first-in-class finite option with a 26 October 2026 PDUFA (priority review + Breakthrough Therapy) hands GSK a near-term launch catalyst and validates Ionis's partnered-antisense platform and royalty stream.
- Source: GSK / Ionis
|
Everything Else that broke
- FDA extends its review of AstraZeneca's camizestrant (oral SERD) in 1L ESR1-mutant HR+/HER2− breast cancer after April's negative ODAC vote; new ctDNA-clearance data due at ASCO on 2 Jun. — Fierce
- D&D Pharmatech's zabopegdutide (GLP-1/glucagon) hits 48-week MASH histology endpoints at EASL — 62.5% MASH resolution and 50% fibrosis improvement vs placebo (n=16, Ph2). — Fierce
- Calls grow to add biotechnology to the COINS Act — a move that could sweep up US–China drug-licensing deals. — Fierce
- Ipsen reports late-breaking IQIRVO data in PBC. — PR
- Basilea gets $13M more from BARDA for antibiotic program. — PR
- Repairon cites NEJM publication from BIOVAT-HF trial. — PR
- Anaveon reports ANV600 clinical benefit in EXPAND-1. — PR
- Trogenix doses first patient in TGX-007 glioblastoma trial. — PR
- Leads Biolabs bispecific shows efficacy signals in NSCLC. — PR
- Bridge to Life cites JAMA Surgery study on VitaSmart. — PR
- Kailera looks beyond obesity to MASH after IPO. — BioCentury
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
XL-protein launches spin-off PASylANTA Therapeutics. — PR
VC / Private Financings
- Secretome Therapeutics raises $30M Series A — led by (sole investor) RA Capital Management — to advance STM-01, a neonatal cardiac progenitor-cell therapy for DMD-associated cardiomyopathy and other rare cardiomyopathies, toward pivotal development. — PR
- ClearNote Health closes a $52M Series D (>$185M raised to date) for its epigenomic oncology diagnostics platform; backers include Matthias Westman, Sandy Weill and Stephen Quake. — PR
- Apogee secures up to $1.3B in non-dilutive royalty/debt financing from Blackstone Life Sciences (sole provider) to take zumilokibart into Phase 3 (see The Big 3). — BioCentury
- VERAXA Biotech lines up a $27.5M senior secured note plus a $50M share purchase agreement to support its de-SPAC with Voyager Acquisition Corp (Nasdaq: VACH → VRXA); Swiss oncology developer of bispecific T-cell engagers and ADCs. — PR
IPOs / Follow-Ons
- Kardigan files for a Nasdaq IPO (KARD) to fund three late-stage cardiovascular programs; led by the ex-MyoKardia team, lead asset danicamtiv. — Fierce
- HanchorBio to list on Taiwan Innovation Board at NT$120. — PR
Academic Corner - Bronchial Anthracosis. — NEJM
- Accurate quantification in proteomics with QuantUMS. — Nature Biotech
|
